VANGUARD GROUP INC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$101,325,221
+105.8%
3,407,035
+24.7%
0.00%
+100.0%
Q2 2023$49,243,867
+13.9%
2,732,734
+1.5%
0.00%0.0%
Q1 2023$43,250,575
-1.0%
2,693,062
+12.9%
0.00%0.0%
Q4 2022$43,670,882
-5.6%
2,386,387
+1.3%
0.00%0.0%
Q3 2022$46,284,000
+1.5%
2,356,647
-3.6%
0.00%0.0%
Q2 2022$45,590,000
-1.1%
2,444,514
+16.4%
0.00%0.0%
Q1 2022$46,079,000
-22.6%
2,099,313
+0.1%
0.00%0.0%
Q4 2021$59,572,000
+68.9%
2,096,898
+25.1%
0.00%0.0%
Q3 2021$35,277,000
+24.5%
1,675,881
+11.5%
0.00%0.0%
Q2 2021$28,328,000
+59.3%
1,502,837
+29.1%
0.00%
Q1 2021$17,785,000
+9.4%
1,163,917
+1.0%
0.00%
Q4 2020$16,257,000
-4.0%
1,152,258
+6.6%
0.00%
-100.0%
Q3 2020$16,940,000
-10.6%
1,081,098
+0.0%
0.00%0.0%
Q2 2020$18,941,000
+153.5%
1,081,036
+112.7%
0.00%
Q1 2020$7,471,000
-40.9%
508,217
+0.8%
0.00%
Q4 2019$12,646,000
+66.8%
504,001
-0.0%
0.00%
Q3 2019$7,583,000
-39.9%
504,101
-0.1%
0.00%
Q2 2019$12,614,000
+22.6%
504,539
+11.6%
0.00%
Q1 2019$10,292,000
+25.8%
452,212
+65.8%
0.00%
Q4 2018$8,179,000
+15.1%
272,723
+10.0%
0.00%
Q3 2018$7,103,000247,9230.00%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q4 2021
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders